齐拉西酮治疗老年痴呆精神行为障碍对照研究

目的：探讨齐拉西酮和氟哌啶醇对老年期痴呆患者精神行为症状（BPSD）的疗效和安全性。方法：将60例老年期痴呆伴BPSD患者随机分成两组,分别使用齐拉西酮和氟哌啶醇治疗8周,采用痴呆病理行为评定量表（BEHAVE-AD）,激越行为量表（CMAI）及治疗中出现的症状量表（TESS）评定疗效和不良反应。结果：两组治疗前后BEHAVE-AD和CMAI评分显著下降（P〈0.01）,两组患者之间治疗前后BEHAVE-AD总减分值差异无统计学意义（P〉0.05）,但情感障碍和焦虑两因子减分值差异有统计学意义（P〈0.05）。结论：齐拉西酮和氟哌啶醇治疗老年期痴呆患者BPSD的疗效相当,齐拉西酮的优势在于对情感障碍和焦虑的疗效更加明显,锥体外系不良反应轻。

A comparative study of ziprasidone and haloperidol in the treatment of patients with senile dementia accompanied by mental and behavioral symptoms

Objective： To investigate the clinical efficacy and side effects of ziprasidone and haloperidol for treating behavioral and mental symptoms in elderly patients with dementia. Method： Sixty patients with senile dementia were randomly divided into two groups and treated with ziprasidone or haloperidol for eight weeks. The behavioral pathology in Alzheimer＇s disease rating scale （BEHAVE-AD） ,Cohen Mansfield agitation inventory （CMAI） and treatment emergent symptoms scale （TESS） were used to evaluate efficacy and adverse effects before treatment and at the end of 2nd,4th,6th ,8th week after treatment. Results： The two groups showed decreases significantly in BEHAVE-AD and CMAI score after the treatment （P 0. 01） ,and did not showed significant difference on BEHAVE-AD total score reduction （P 0. 05） ,but on affect disorders and anxiety reduction （P 0. 05） . Conclusion： Ziprasidone has similar efficacy to haloperidol in treatment of senile dementia patients with BPSD with mild adverse reaction.